Search Results

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization

December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company and Crinetics to Collaborate on Multiple Additional targets SAN DIEGO, October 18, 2021 — Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization --Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like

reality is more nuanced, and mastering drug binding kinetics is essential for pipeline efficiency: How fast

July 2022 "Not even a PIPE financing could save X4 Pharmaceuticals from enacting layoffs and trimming

November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals , Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has successfully completed

June 2022 "CRN04894 Selected for Oral Presentation SAN DIEGO, June 8, 2022 — Crinetics Pharmaceuticals

with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery "Apr.19.2022 Ono Pharmaceutical

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical The NDA was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa

scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who need fast

monoclonalantibodies #drugdiscovery #biotechnology #research #ionchannels #biologics #biotech #pharma #pharmaindustry #pharmaceuticals

Born near Venice and trained as a pharmaceutical chemist, Alessandro never imagined himself working at The Early Days: Molecules and Mentors Alessandro began his academic life studying pharmaceutical chemistry

elusive GPCR targets, financial results from Neurocrine Biosciences, and a deep dive into Crinetics Pharmaceuticals ➤ Yamina's Consulting Corner - Building Your GPCR Program for Breakthroughs, Not Breakdowns In the fast-paced world of GPCR drug discovery, the "go fast" mindset can often lead to costly breakdowns. scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who need fast Yamina's Corner, biotech, systems thinking, signal transduction, operational excellence, drug development, pharmaceutical

She studied pharmacy with a specialization in pharmaceutical chemistry, a degree that allowed her to

Therapeutics To Release Half-Year 2023 Financial Results And Host Conference Call On August 10, 2023 X4 Pharmaceuticals adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results And Provides Corporate Update X4 Pharmaceuticals Announces

Nordisk looks to next generation of obesity, diabetes drugs with $550M Replicate research deal; Rhythm Pharmaceuticals GPCR Premium: Sneak Peek A fast, editorial preview—enough to guide your attention, not replace your due translational pharmacologists, biotech discovery teams, platform company leaders, and decision-makers who need fast

- 4, 2024 | Chemotactic Cytokines GPCR Jobs NEW Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals NEW Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

not only deepens our understanding of a key biological process but also provides a valuable map for pharmaceutical Beyond GPCRs, the methods and insights from this study can be applied to other fast, transient biological

Jobs NEW Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Apprentice Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical

recently had the pleasure of speaking with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

research in biomedical sciences with the mechanistic understanding of one of the biggest classes of pharmaceutical

GPCR Jobs Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

"Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical

Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical

Discount:  25% off for Premium Members—Act Fast! Structural analysis of the human C5a-C5aR1 complex using cryo-electron microscopy Industry News Crinetics Pharmaceuticals

Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 Crinetics Pharmaceuticals Cushing’s Syndrome (ADCS) Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals

Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical